Merck & Co., Inc. 13D and 13G filings for Evaxion Biotech A/S:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-03 4:15 pm Purchase |
2025-01-31 | 13G | Evaxion Biotech A/S EVAX |
Merck & Co. Inc. MRK |
63,004,142 19.960% |
61,460,024 (+3980.27%) |
Filing |
| 2024-11-06 4:09 pm Purchase |
2024-09-30 | 13G | Evaxion Biotech A/S EVAX |
Merck & Co. Inc. MRK |
1,544,118 12.900% |
625,000 (+68.00%) |
Filing |
| 2024-01-23 3:29 pm Purchase |
2023-12-21 | 13G | Evaxion Biotech A/S EVAX |
Merck & Co. Inc. MRK |
919,118 11.400% |
919,118 (New Position) |
Filing |